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Abstract
Background Recent studies have reported an association
between maternal use of gastric acid-suppressive drugs
during pregnancy and asthma in the offspring, but the
association could have been confounded by unmeasured
risk factors.
Objective We assessed the association between the use of
acid-suppressive drugs during pregnancy and the risk of
developing childhood asthma using a bidirectional cross-
over design.
Methods Mother–infant matched sets in the UK General
Practitioners Research Database were used to identify
children with a drug-treated asthma diagnosis during the
years 2006–2010 who were matched to a sibling without
asthma as controls. Primary exposure was use of any anti-
suppressive drug during pregnancy, and subgroup analyses
were conducted according to drug class (e.g. proton pump
inhibitors or histamine 2 receptor antagonists) and trimes-
ter. Conditional logistic regression was used to estimate
odds ratios (OR) with their corresponding 95 % confidence
intervals (CIs).
Results A total of 1,874 children with asthma and 1,874
control siblings were included in the analysis. The expo-
sure rate among case and control pregnancies was 22 and
20 %, respectively. After adjustments for gender, birth
order, mother’s age and general practice visits, the expo-
sure to any gastric-acid suppressive drug during pregnancy
slightly increased the risk for developing asthma (OR 1.23,
95 % CI 1.01–1.51; p = 0.042). A trend towards increased
risks was observed for those who used proton pump
inhibitors and/or histamine 2 receptor antagonists (adjusted
OR 1.72, 95 % CI 1.00–2.98; p = 0.048).
Conclusions These findings lend support to the emerging
evidence that exposure to acid-suppressive drugs during
pregnancy is associated with childhood asthma. More basic
research is now warranted to investigate the mechanisms.
1 Introduction
Asthma is a prevalent disease in childhood and a significant
cause of morbidity [1]. In the UK, it has been estimated
that up to 11 % of all children have one or more allergic
diseases, asthma being a common disease entity [2].
Importantly, asthma incidence has increased over decades,
with large variations between countries, suggesting that
increased exposure to environmental factors may play a
role [3, 4]. Lately, there has been an interest in the role of
the prenatal environment in the aetiology of asthma [5].
Epidemiological studies have suggested that the key time
period for childhood allergies and asthma development
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occurs between conception and early childhood, and pre-
natal drug use has also been implicated [6, 7].
During pregnancy gastrointestinal symptoms are com-
mon, and proton pump inhibitors (PPIs) and histamine 2
receptor antagonists (H2ra) and, to a lesser extent, other
antacids are effective against such symptoms [8]. Dehlink
and colleagues [9] were the first to hypothesize that the use of
acid-suppressive therapy during pregnancy may cause the
development of asthma in offspring. The investigators found
that exposure to acid-suppressive drug therapy was associ-
ated with development of childhood asthma, with a statisti-
cally significant odds ratio (OR) of 1.51, but residual
confounding by unmeasured risk factors could not be ruled
out. Andersen and colleagues [10] followed up on this study
and reported an increased risk of childhood asthma after in-
utero exposure to PPIs in a cohort of Danish women, with an
estimated OR of 1.41. Because the observed association was
not drug specific and was also observed for maternal postnatal
use, the authors stated that the association could be explained
by a ‘class effect’ or underlying maternal condition. Recently,
Ka¨lle´n and colleagues [11] also observed an increased risk
between drugs for gastroesophageal reflux in pregnancy and
childhood asthma (adjusted OR 1.32), but asthma in the
mother could have confounded the association. Prior to the
current study, we conducted a crossover and case-control
study in The Netherlands using the University of Groningen
mother–infant drug prescription database, which yielded
results for use of either PPIs or H2ra similar to those in the
earlier studies, but asthma could only be defined by the pre-
sence of respiratory prescriptions [12].
The study of drug therapy in pregnancy and subsequent
risks of asthma in the offspring is complicated. The
development of asthma depends on a complex interaction
between genetic and various environmental risk factors.
For example, the presence of asthma in the mother, life-
style factors such as smoking during pregnancy, or pre-
term delivery all have been found to increase the risk of
asthma [13]. The distribution of these potential risk factors
may well be different between pregnant women who use
acid-suppressive drug therapy and those who do not, and
this may lead to confounding bias [14]. We designed a
study to further evaluate acid-suppressive drug use during
pregnancy and development of childhood asthma in the
offspring where the potential for confounding bias was
limited through the use of a bidirectional crossover design.
2 Methods
2.1 Setting and Study Design
This crossover study was conducted using data from the
UK General Practice Research Database (GPRD), which is
administered by the Medicines and Healthcare Products
Regulatory Agency and has been previously described in
detail [15–17]. In brief, the GPRD contains electronic
medical records for a nationally representative group of
British residents currently enrolled in more than 450 gen-
eral practice offices in the UK. General practitioners (GPs)
who participate in the GPRD have agreed to provide
patient data for research purposes and are trained to
accurately record information about patient demographics,
medical diagnoses and procedures that are part of routine
care or resulting from hospitalizations, results of laboratory
and pathology testing, and referrals to hospitals and spe-
cialists. In the UK, ‘Read’ codes, which are more extensive
than the ICPC (International Classification of Primary
Care) coding system and agree with the International
Classification of Diseases, tenth revision (ICD-10) classi-
fication system, are used by GPs to classify medical diag-
noses. The quality and completeness of the information
recorded in the GPRD has been widely validated [15–17].
We linked mothers within the GPRD to their children using
a unique family identification number and the dates of
delivery in the mother’s record in combination with the
dates of birth in her children’s records. This mother–baby
linkage was used in a previous study on maternal drug
exposures and asthma in the child [18].
We designed a non-traditional nested crossover study,
which is a modification of the case-crossover design first
introduced by Maclure in 1991 [19]. The conventional
approach is to compare the exposure prior to the case-
defining event with the same individual’s exposure at ref-
erent time points when he or she did not experience the
event. By making within-person comparisons, all measured
and unmeasured time-invariant confounders are controlled
for in the design. We adopted a ‘bi-directional cross-over’
design or ‘within-mother-between-pregnancy’ design [20–
22] using sibling cases and controls born in different order
from the same mothers to control for any bias by exposure
trends within the traditional studies [22].
2.2 Source Population
The source population for the study comprised all mothers
and their infants who were linked in the mother–infant
subset of the GPRD. The study period for case detection
covered the years 1996 through 2010. Mothers with mul-
tiple singleton births, who were aged between 15 and
40 years in the year of delivery of their first infant, were
included. Mothers were required to have a recorded history
of 12 months or more prior to the birth of their first child
and to have at least two children. Each child was required
to have at least 3 years of follow-up in the data after birth.
Mothers who conceived a baby with a congenital birth
defect or chromosomal anomaly or who had a history of
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use of known teratogens, including antineoplastics, anti-
convulsants, retinoids, angiotensin-converting enzyme
inhibitors, anticoagulants, tetracyclines, antithyroid drugs
and lithium, were excluded. Since teratogen use could
seriously confound or modify our findings, we decided a
priori not to include this relatively small group of women.
All codes and relevant prescriptions are provided in the
Appendix (see the Electronic Supplementary Material).
2.3 Case and Control Definition
Asthma cases were defined as children who received a first
diagnosis of asthma any time between birth and 14 years of
age (see the Electronic Supplementary Material for Read
codes) and who were prescribed any asthma drug at least
three times (see the Electronic Supplementary Material for
prescription drugs) within 12 months after first asthma
diagnosis date, which defined the index date. The minimum
number of three prescriptions was included to reduce the
chance of false-positive case selection. Pont et al. [23], for
example, studied sensitivity, specificity and predictive
values of drug medications for identifying patients with
asthma. A prescription for one or more anti-asthma medi-
cations identified 95 % of patients with an asthma diag-
nosis (positive predictive value 0.70), while two or more
anti-asthma medications identified 71 % (positive predic-
tive value 0.79). Since asthma patients can be reliably
identified from prescribing data, we decided to use a def-
inition that was even more specific (three prescriptions
instead of two prescriptions) to avoid including cases
without asthma and to provide a clear comparison with
controls with no asthma drugs or diagnosis codes. Children
from the mother–infant subset who were born to the same
mother as a case child (before or after) were used as con-
trols if they had neither a history of childhood asthma nor
any prescription for asthma in their medical history. The
control siblings were required to be present in the database
at an age similar to that of the case (±1 year) at first
diagnosis of asthma (index date). We included only
mothers who had a pair of one eligible case and one eli-
gible control. We excluded a few mothers (N = 47) who
had more than one eligible control, e.g. twins, from further
data analysis.
2.4 Exposure Status and Covariates
The exposure of interest was the prescription of any acid-
suppressive drug therapy during pregnancy (see the Elec-
tronic Supplementary Material for specific drugs) defined
as receipt of one or more prescriptions for any gastric acid-
suppressive drug just prior to or during any trimester of
pregnancy. We estimated the date of conception by sub-
tracting 270 days from the delivery date because the date
of conception was unavailable. Exposure at any time dur-
ing pregnancy was defined as 0–335 days prior to the
delivery date to include drugs prescribed prior to concep-
tion that could have been taken during early pregnancy.
Exposure during the first trimester was further classified as
a prescription between 180 and 335 days prior to the
delivery date, for the second trimester between 90 and
179 days, and for the third trimester between 0 and
89 days. Non-exposure was defined as absence of any
prescription for an acid-suppressive drug during pregnancy
(between 0 and 335 days prior to the delivery date).
Exposure was further grouped into PPIs, H2ra, and other
antacids; categories were not mutually exclusive. Women
could have used more than one drug at the same time and/
or during different trimesters. We also evaluated exposure
according to trimester (first and second vs. third), since,
patho-physiologically, lungs are being developed during
the first and second trimester, whereas immune response
matures toward the end of pregnancy.
Covariates in the study were selected on the basis of
subject matter knowledge and previous studies on this topic
[9–13]. We collected information on the child’s gender and
potential confounders such as age of the mother at delivery,
birth order, body mass index (BMI), smoking status, pre-
sence of migraine, pre-eclampsia or the prescription of
paracetamol or non-steroidal anti-inflammatory drugs
(NSAIDs) during pregnancy, or any prescription for any
acid-suppressive medication in the child prior to the index
date. The number of practice visits prior to delivery was
also recorded as a proxy for healthcare use. A diagnosis of
preterm delivery or low birth weight was also recorded as
an indicator of risks for asthma development.
2.5 Data Analysis
We conducted conditional logistic regression analyses to
obtain ORs and their corresponding 95 % confidence
intervals (CIs) of the association between PPI exposure in
the mother and the diagnosis of childhood asthma. In the
primary analysis, we first modeled the primary exposure-
outcome association adjusted for confounders. Then, sep-
arate causal models were made for the explorative expo-
sure-outcome associations. Confounders were selected if
they were both associated with the outcome and the
exposure on the basis of the p-value (\0.05) or based on
knowledge of the subject matter. To further address the
potential for residual bias and effect modification, relevant
explorative subgroup analyses without formal tests for
interaction were conducted according to acid-suppressive
drug type (PPI, H2ra and other) and trimester (first and
second vs. third). We conducted the statistical analyses
using the software program SAS, Version 9.1 (SAS Insti-
tute, Inc., Cary, NC, USA).
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3 Results
We identified 1,874 mothers who had 1,874 children with
asthma and one qualifying control sibling without asthma.
The mean age of the mothers was 28.2 years and the mean
age at first diagnosis of asthma in the offspring was
3.6 years. Cases were more often male and first born, and
their mothers were statistically significantly younger dur-
ing the case’s pregnancy than during the control pregnancy
and had fewer GP visits during the case pregnancy than
during the control pregnancy (see Table 1). All other
covariates were similarly distributed.
The distribution of covariates was similar in control
children exposed to acid-suppressing drugs and those not
exposed except for BMI, mother’s age and paracetamol
use. There was a significantly higher prevalence of high
BMI and higher use of paracetamol and a near significant
younger age of the mother in the exposed than in the
unexposed pregnancies (see Table 2).
Twenty-two percent of children with asthma had
mothers who were exposed to any acid-suppressive drug
during pregnancy (see Table 3). The corresponding figure
for the control group was 20 %. After adjustment for
gender of the child, birth order, age of the mother and
number of GP visits, the exposure to any acid-suppressive
drug during pregnancy was associated with a small but
statistically significant increased odds for developing
childhood asthma (adjusted OR 1.23, 95 % CI 1.01–1.51;
p = 0.042). Stratified analysis indicates that this effect was
restricted to exposure in the third trimester (adjusted OR
1.29, 95 % CI 1.03–1.62; p = 0.029). Analyses according
to subgroups of acid-suppressive drugs indicated that those
who used PPIs and/or H2ra during pregnancy had higher
risks of a child who developed asthma (adjusted OR 1.72,
95 % CI 1.00–2.98; p = 0.048). Though not statistically
significant, the analysis of PPI use alone yielded the highest
risk for asthma (OR 2.76, 95 % CI 0.98–8.17).
4 Discussion
4.1 Main Findings
These results suggest that the use of gastric acid-suppres-
sive medications during pregnancy is associated with an
increase in the risk for development of asthma in the child.
The trend towards increased risk was present in children of
women exposed to PPIs and/or H2ra and when the expo-
sure occurred during the third trimester of pregnancy.
4.2 Strengths and Limitations
Major strengths of the study include the use of the widely
researched GPRD, which contains accurate information on
diagnoses and prescriptions and large numbers of patients.
The GPRD also contains a family identification number,
making it possible to link mothers and their infants. Fur-
ther, using the cross-over design, we were able to control
for many potential confounders inherent in observational
studies of this topic. While mothers taking acid-suppressive
Table 1 Distribution of
covariates in children with
asthma (cases) and control
siblings
BMI body mass index, GP
general practitioner, NA not
applicable, NSAIDs non-
steroidal anti-inflammatory
drugs, SD standard deviation
a Data on BMI were missing for
877 patients
b Data on smoking were









Male gender 1,110 (59) 843 (45) \0.001
Mean age at first asthma diagnosis 3.6 years NA NA
Mean number of asthma drugs in 12 months 15 0 NA
First-born 991 (53) 728 (39) \0.001
Use of antacids prior to index date 22 (1.2) 29 (1.7) 0.32
Low birth weight/prematurity 28 (1.5) 18 (1.0) 0.14
Pregnancy characteristics
Mean age (SD) in years 27.9 (5.2) 28.6 (5.2) \0.001
Presence of asthma 89 (5) 90 (5) 0.94
Presence of migraine 33 (2) 32 (2) 0.90
Presence of (pre-)eclampsia 1 (0.05) 0 (0) 0.32
High BMI ([35)a 148 (10) 165 (11) 0.39
Current smokerb 470 (29) 459 (28) 0.51
Mean number of GP visits during pregnancy 11.4 (7.4) 11.9 (7.6) 0.03
Use of paracetamol 256 (14) 259 (14) 0.89
Use of NSAIDs 49 (3) 50 (3) 0.91
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therapy may have differential risks than non-exposed
mothers such as genetic predisposition, smoking or other
risk behaviours and co-morbidities that could be associated
with asthma, and which may have led to confounding bias
in previous studies [9–11], these factors were controlled in
the study design. Importantly, treatment of gastroesopha-
geal reflux disease (GERD) symptoms has been associated
with improvement in asthma. Thus, prescriptions for acid-
suppressing medication could be a proxy for presence of
asthma in the mother, which itself is a risk factor for
asthma development in the child. The current study design
controls for this potential bias by having the same mother
for both siblings in each case–control pair. We examined
samples of medical records of the mothers for information
on additional potential confounding factors and took these
into account by either matching or multivariate adjust-
ments. By design, we showed that these measured risk
factors were similarly distributed among exposed and
unexposed and had only a small influence on the estimated
associations. It is therefore highly unlikely that residual
confounding by unmeasured factors could explain our
findings.
There are also limitations to our study. Though odds
ratios were materially elevated for PPIs and H2ra, the OR
Table 2 Distribution of
covariates in unexposed and
exposed pregnancies estimated
from control pregnancies in the
crossover analysis (N = 1,874).
Number (percentages) are given
unless stated otherwise
BMI body mass index, GP
general practitioner, NSAIDs
non-steroidal anti-inflammatory
drugs, SD standard deviation
a Data on BMI were missing for
877 patients
b Data on smoking were









Male gender 676 (45) 167 (46) 0.82
First-born 584 (39) 144 (39) 0.86
Use of antacids prior to index date 18 (1) 4 (1) 0.87
Low birth weight/prematurity 16 (1) 2 (0.5) 0.36
Pregnancy characteristics
Mean age (SD) in years 28.5 (5.3) 29.0 (4.9) 0.07
Presence of asthma 75 (5) 15 (4) 0.48
Presence of migraine 23 (2) 9 (2) 0.22
Presence of (pre-)eclampsia 0 0 –
High BMIa 122 (11) 43 (15) 0.03
Current smokerb 376 (29) 83 (26) 0.36
Mean number of GP visits 11.5 (8) 13.5 (7) 0.85
Use of paracetamol 194 (13) 65 (18) 0.02
Use of NSAIDs 38 (3) 12 (3) 0.43
Table 3 Unadjusted and adjusted conditional odds ratios for the development of childhood asthma after exposure to acid-suppressive drug
during pregnancy
Cases (N = 1,874)
N (%)
Controls (N = 1,874)
N (%)
Unadjusted conditional
OR (95 % CI)
Adjusted conditional
OR (95 % CI)a
Exposure to any acid-suppressive drug 405 (22) 367 (20) 1.20 (1.00–1.45) 1.23 (1.01–1.51)
Subgroup of acid-suppressive drugsb
PPIs or H2ra 42 (2.2) 33 (1.8) 1.36 (0.81–2.28) 1.72 (1.00–2.07)
PPI 13 (0.7) 7 (0.4) 2.20 (0.76–6.33) 2.76 (0.93–8.17)
H2ra 33 (1.8) 28 (1.5) 1.24 (0.70–2.2) 1.56 (0.85–2.90)
Other 378 (20.1) 347 (18.5) 1.17 (0.96–1.42) 1.16 (0.95–1.42)
Trimesterc
First/second 213 (11) 213 (11) 1.0 (0.77–1.21) 1.01 (0.79–2.08)
Third 304 (16) 267 (14) 1.25 (1.01–1.56) 1.29 (1.03–1.62)
CI confidence interval, OR odds ratio, PPI proton pump inhibitor, H2ra receptor antagonists
a Adjusted for gender, birth order, age of the mother at birth and number of GP visits during pregnancy
b In few pregnancies, more than one subgroup of drugs were prescribed
c Women could take more than one prescription per trimester
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was smaller overall, which suggests a class effect, but we
had inadequate statistical power to formally test this. It is
possible that we missed some exposures, because of over-
the-counter use without prescription, though in the UK
during pregnancy such exposures should be only a small
proportion of all acid-suppressive drug use. In The Neth-
erlands, for example, which has a similar healthcare system
as the UK, use of over-the-counter drugs is low among
pregnant women and we believe that this has had no major
influence on our findings [24]. Also, we assumed that all
prescribed medications were actually taken. Since exposure
misclassification is likely random, this should not have
materially affected our findings. Second, it is possible that
we missed some children who had undiagnosed asthma
because they did not seek medical attention, or mild asthma
not treated chronically as was required by our definition
including drug treatment. Overall, while such errors in
identifying cases may lead to bias in estimating incidence
rates, they will usually have little impact on ORs estimated
from case–control studies. Further, some asthma cases
might not have an allergic component. However, it is well
known that this is a minority and more than 80 % of
asthma is allergic. Importantly, potential selection bias was
also minimized because children were followed for at least
3 years and both cases and controls were required to have
the same length of follow-up. Since information on the
conception date was unavailable to the researchers, in
accordance with other pregnancy studies, we applied a
standardized period of 335 days to define the pregnancy
duration [18]. Such standardization may also have led to
some small amount of exposure misclassification, which
could have resulted in a minimal overestimation of actual
use. By design, we could only examine families with two
or more children and those without teratogen use. Our
findings do not necessarily apply to smaller families or
pregnant women who use teratogens. Of note, it is not
known how the ORs from a crossover design would cor-
respond to the actual risk in the general population of acid-
suppressant users as measured, for example, using a cohort
or conventional case–control design. By definition, in the
crossover design, each case and matched control had the
same mother and thus differences in mothers’ susceptibility
were controlled. Hence, the study population may have
been a subsample of the population where the effect of
acid-suppressive drugs may be stronger than in the general
pregnant population. Though by design the potential con-
founding effect of asthma in the mother is largely con-
trolled for, it is possible for a woman to have a period of
particularly poor asthma control during one of the two
pregnancies, leading to an increased risk of childhood
asthma and acid-suppressive drug use in only one of the
two offspring. Data to control for asthma severity are not
routinely available, and future studies should examine the
potential impact of disease status and also look at the
exposure pre-pregnancy-outcome association as a negative
control. Indeed, in our prescription database study, a pre-
pregnancy exposure-outcome association was absent [12].
4.3 Comparison with Other Studies and Hypotheses
The observed association between prenatal exposure to
acid-suppressive drug and asthma in our study is consis-
tent with the findings of Dehlink et al. [9], Andersen et al.
[10] and Ka¨lle´n et al. [11] and also with findings from an
unpublished study using a case-crossover design in the
University Groningen pregnancy database in which we
defined cases as toddlers who were prescribed asthma
medications at least two times before the age of 5 years
[12]. Since we showed the minimal influence of con-
founding in the associations, the validity of earlier reports
is supported by our findings. The precise mechanisms by
which acid-suppressive drugs may cause asthma are
hypothetical. It has been proposed that neutralized gastric
acid levels prevent adequate digestion of antigens in the
adult stomach. While antigens normally degrade into
oligopeptides to enter the gastrointestinal tract, these can
now induce a T-helper (Th)-2 response and immunoglobin
(Ig)-E sensitization of the immune system [25–27]. If
crossing the placenta, these antigens could induce allergic
sensitization of the foetus [28]. This hypothesis is sup-
ported by a study in pregnant mice showing a Th2-dom-
inant immune response in the offspring caused by gastric
acid suppression [29]. The development of the foetal
immune system is also influenced by the allergic state of
the mother. The dominant Th2 cytokine phenotype in
allergic mothers was present in the cord blood, which
could promote an allergy-prone phenotype in the foetus
[30]. Also, maternal IgE can cross foetal membranes and
sensitize immune cells of the foetus to allergens [31].
Alternatively, it may be hypothesized that the develop-
ment of lung tissue may directly be damaged by these
drugs by another unknown mechanism. However, the first
hypothesis seems more likely given that the associations
in our study were significant, especially during the later
trimester, in which the immune system in particular
develops, but more study, for example, of the mechanism
or development of other atopic conditions in relation to
acid-suppressive drug use, is now warranted.
5 Conclusion
These findings lend support to the emerging evidence that
exposure to acid-suppressive drugs during pregnancy is
associated with childhood asthma. More basic research is
now warranted to investigate the mechanisms.
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